113 reports of adverse drug reactions induced by fluoroquinolones in patients with tuberculosis

doi:10.19803/j.1672-8629.2022.04.13

Abstract

Abstract: Objective To analyse the adverse drug reactions (ADR) reports induced by fluoroquinolones in patients with tuberculosis, so as to provide reference for rational drug use. Methods The cases of ADR induced by fluoroquinolones in patients with tuberculosis from January 1, 2013 to June 30, 2020 in our hospital were retrospectively investigated and analyzed. Results A total of 113 cases of ADR of fluoroquinolones were reported in tuberculosis patients, of which serious ADR accounted for 10.62%. Three kinds of fluoroquinolones were involved, levofloxacin, enoxacin, and moxifloxacin in turn. Clinical manifestations involved skin and appendages disorders, systemic reaction, gastrointestinal system. ADR induced by intravenous administration was more than oral administration. 7.08 % of the patients had irrational drug use, which manifested as unsuitable selection of drugs. Conclusion The monitoring of ADR of fluoroquinolones in tuberculosis patients should be attached great importance in clinical treatment, and effective measures should be taken timely to improve the safety of drug use.

Key words: fluoroquinolones, levofloxacin, enoxacin, moxifloxacin, adverse drug reaction, pharmacovigilance

CLC Number:

R974

ZHU Na, KAN Xiaohong, WU Xinli, DING Haihua, XUE Shuya, ZHANG Yunling. 113 reports of adverse drug reactions induced by fluoroquinolones in patients with tuberculosis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 404-407.

References

[1] World Health Organization.Global tuberculosis report 2020[EB/OL].(2020-10-27)[2021-03-20].https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2020.
[2] Chinese Medical Association.Guidelines for clinical treatment: tuberculosis volume(临床诊疗指南:结核病分册)[M]. Beijing: People's Medical Publishing House, 2005: 65, 80.
[3] TAN SY, LI YQ.Application of fluoroquinolones in the treatment of multidrug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis(中国防痨杂志), 2005,27(4): 267-270.
[4] Chinese Antituberculosis Association. Chinese Antituberculosis Association(2019)[J]. Chinese Journal of Antituberculosis(中国防痨杂志), 2019, 41(10): 1025-1073.
[5] DOOSOO J.WHO treatment guidelines for drug-resistant tuberculosis,2016 update: applicability in South Korea[J]. Tuberculosis & Respiratory Diseases, 2017, 80(4): 336-343.
[6] SONG WJ.Clinical analysis of adverse reactions of fluoroquinolones[J]. Chinese Journal of Modern Drug Application(中国现代药物应用),2015, 9(15): 158-159.
[7] FAN M.Literature analysis on ADR induced by quinolones in the elderly[J].China Pharmacy(中国药房), 2010, 21(18): 1704-1706.
[8] Jiao WW, Sun L, Xiao J, et al.Guidelines for national tuberculosis programmes-management of tuberculosis in children(version 2)[J]. Chinese Journal of Evidence Based Pediatrics(中国循证儿科杂志),2016, 11(1): 65-74.
[9] YANG XJ, XIE HT, WANG HF.Analysis of 176 new and severe ADR reports[J]. China Pharmacy(中国药房), 2014, 25(14): 1301-1303.
[10] TAN LL.Clinical adverse reactions of quinolone antibacterial drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2013, 10(2): 92-95.
[11] National Medical Products Administration. Adverse drug reactions information bulletin (Issue 58) focuses on serious adverse reactions to fluoroquinolones [EB/OL]. (2013-11-21)[2021-03-14]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20131121120001488.html.
[12] National Medical Products Administration. Notice of the General Administration of the People's Republic of China on the Revision of the instructions for fluoroquinolones for whole body use (No. 79, 2017)[EB/OL]. (2017-07-05)[2021-03-14].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypshmshxdgg/20170705171401817.html.
[13] CHANG XY, GUO GM.Analysis of literature on adverse reactions to thrombocytopenia induced by quinolones[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(4): 227-230.
[14] LINDEN PDVD, STURKENBOOM MCJM, HERINGS RMC.et al.Fluoroquinolones and risk of Achilles tendon disorders: case-control study[J]. British Medical Journal, 2002, 324(7349): 1306-1307.
[15] SHU CHEN K, YUNG TAI C, YI TZU L, et al.Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study[J]. Clinical Infectious Diseases, 2014, 58(2): 197-203.
[16] MEHRZAD R, BARZA M.Weighing the adverse cardiac effects of fluoroquinolones: a risk perspective[J]. Journal of Clinical Pharmacology, 2015, 55(11): 1198-206.
[17] LIN X, LI J, REN HL.Analysis of 481 reports of adverse drug reactions induced by quinolone drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(10): 617-624.